8.4 Drug Product Conditions Prohibiting Dispensing: Recalls, Outdated Stock & Adulteration
Key Takeaways
- N.J.A.C. 13:39-7.18 governs outdated drugs and drugs marked 'sample,' and the registered pharmacist-in-charge must ensure that no misbranded, deteriorated, adulterated, improperly stored, or outdated drug — and no drug marked 'sample' — is dispensed or present in the pharmacy's active stock.
- N.J.A.C. 13:39-7.5 conditions dispensing on FDA approval, so an unapproved product is outside the pharmacist's dispensing authority regardless of prescriber intent.
- N.J.A.C. 13:39-7.13 preserves the pharmacist's right to refuse to fill where the prescription is outside the prescriber's scope of practice, where there is sufficient reason to question its validity, or where refusal protects the health and welfare of the patient.
- FDA classifies recalls by health consequence: Class I carries a reasonable probability of serious adverse health consequences or death, Class II involves temporary or medically reversible consequences, and Class III is unlikely to cause adverse health consequences.
- Under the DSCSA, product identified as suspect must be quarantined and investigated, and product determined to be illegitimate triggers notification to FDA on Form 3911 and to immediate trading partners within 24 hours.
8.4 Drug Product Conditions Prohibiting Dispensing: Recalls, Outdated Stock & Adulteration
[!NOTE] Core Legal Authorities: Outdated drugs or drugs marked "sample" (N.J.A.C. 13:39-7.18), approval of FDA necessary (N.J.A.C. 13:39-7.5), professional judgment in dispensing drugs (N.J.A.C. 13:39-7.13), disposal of unwanted drugs (N.J.A.C. 13:39-7.17), the pharmacist-in-charge's stock-integrity duties under the Board's pharmacy operation rules, the federal Food, Drug, and Cosmetic Act adulteration and misbranding provisions (21 U.S.C. §§ 351 and 352), FDA recall classification (21 CFR Part 7), and the Drug Supply Chain Security Act suspect and illegitimate product provisions.
Most of this guide addresses whether a prescription is valid. This section addresses a different question that the MPJE blueprint isolates as its own competency: whether the product on the shelf may lawfully be dispensed at all. A perfectly valid prescription for a perfectly appropriate drug still cannot be filled from an expired, recalled, adulterated, or unapproved container.
Six Conditions That Bar Dispensing
+---------------------------------------------------------------------------+
| IS THIS PRODUCT LEGALLY DISPENSABLE? SIX DISQUALIFIERS |
+---------------------------------------------------------------------------+
| 1. OUTDATED — past the labeled expiration or assigned BUD |
| 2. DETERIORATED — physical or chemical degradation, improper storage |
| 3. ADULTERATED — contamination, cGMP failure, unsanitary conditions |
| 4. MISBRANDED — false/misleading labeling, missing required information |
| 5. SAMPLE — marked "sample" or any like designation |
| 6. RECALLED / — subject to a manufacturer or FDA recall; or suspect or |
| ILLEGITIMATE illegitimate product under the DSCSA |
+---------------------------------------------------------------------------+
New Jersey states the rule as an inventory duty, not merely a dispensing duty. The registered pharmacist-in-charge must ensure that no misbranded, deteriorated, adulterated, improperly stored, or outdated drug — and no drug marked "sample" or with any like designation — is dispensed or is present in the active stock of the pharmacy. The phrase present in the active stock is the one that generates citations: it is a violation to have the product on the working shelf even if nobody ever dispenses it.
N.J.A.C. 13:39-7.18 governs outdated drugs and drugs marked "sample" specifically, and N.J.A.C. 13:39-7.17 supplies the disposal route once product is pulled.
Adulteration and Misbranding: Two Different Defects
Candidates conflate these constantly, and the exam separates them.
| Adulterated (21 U.S.C. § 351) | Misbranded (21 U.S.C. § 352) | |
|---|---|---|
| What is wrong | The product itself — contamination, filth, degradation, strength or purity differing from what it purports to have, preparation under insanitary conditions or in violation of cGMP | The labeling or information — false or misleading labeling, missing required elements, no adequate directions for use, failure to bear the required warning |
| Typical pharmacy example | A cream compounded in a soiled work area; a product stored outside its labeled temperature range | A dispensed vial lacking the required auxiliary warning or the controlled substance transfer warning; a repackaged product with an inaccurate label |
| Fix available? | Generally no — the product is compromised | Sometimes: correcting the labeling can cure the defect before dispensing |
Both are federal violations, and both independently make the product undispensable in New Jersey through the stock-integrity duty.
Expiration Dates, Beyond-Use Dates & Deterioration
- The manufacturer's expiration date applies to the product in its original, unopened container under labeled storage conditions.
- Once the pharmacy repackages the product for a patient, the beyond-use date governs, and the New Jersey labeling rule caps the BUD on a dispensed container at one year from dispensing or the manufacturer's expiration date, whichever is shorter.
- Deterioration is independent of the date. A product stored above its labeled range, or showing caking, discoloration, or precipitation, is undispensable even if the printed date has not passed. This is why the temperature logs discussed in the facility chapter are enforcement documents: they are the evidence that refrigerated and controlled-room-temperature stock stayed within range.
FDA Approval Is a Precondition
N.J.A.C. 13:39-7.5 makes FDA approval necessary. The practical consequence is that a pharmacist confronted with a prescription for a product that has not been approved — an unapproved imported drug, for example — cannot cure the problem by confirming that the prescriber really meant it. Prescriber intent does not supply an approval the product lacks. The relationship to compounding is worth holding in mind: a 503A pharmacy compounding pursuant to a valid prescription operates under a statutory exemption from premarket approval, which is a different legal posture from dispensing an unapproved commercial product.
Recalls: Classes and Pharmacy Response
FDA classifies recalls by the health consequence of the defect, not by the size of the recall:
| Class | Definition | Pharmacy Posture |
|---|---|---|
| Class I | A reasonable probability that use of the product will cause serious adverse health consequences or death | Immediate quarantine; identify and contact patients who received affected lots |
| Class II | Use may cause temporary or medically reversible adverse health consequences, or the probability of serious consequences is remote | Quarantine; patient notification per the recall notice and clinical judgment |
| Class III | Use is not likely to cause adverse health consequences | Quarantine and return per the notice; patient notification usually not indicated |
A market withdrawal is a separate category — removal of a product for a minor violation not subject to FDA legal action, or for a reason unrelated to a violation.
The New Jersey Recall Trap
The re-dispensing rule at N.J.A.C. 13:39-7.16(c) contains a directive that appears on exams: if the manufacturer or the FDA orders a recall, the pharmacist shall assume that products held in labeled containers without lot numbers are included in the recall and proceed accordingly. Repackaged product from abandoned prescriptions frequently lacks a manufacturer lot number, and the rule resolves that ambiguity against dispensing.
Suspect and Illegitimate Product Under the DSCSA
The supply-chain chapter covers the transaction documentation; the dispensing consequence belongs here.
- Suspect product — reason to believe it is counterfeit, diverted, stolen, intentionally adulterated, or unfit for distribution: quarantine immediately and investigate.
- Illegitimate product — credible evidence confirms it: quarantine, notify FDA using Form 3911 and notify immediate trading partners within 24 hours, and do not dispense.
- Pharmacies may trade only with Authorized Trading Partners, so product acquired outside that channel is suspect by origin.
The Pharmacist's Independent Refusal Authority
N.J.A.C. 13:39-7.13 is short and worth knowing close to verbatim: the pharmacist shall have the right to refuse to fill a prescription if, in the pharmacist's professional judgment, the prescription is outside the scope of practice of the prescriber; or if the pharmacist has sufficient reason to question the validity of the prescription; or to protect the health and welfare of the patient.
That third clause is broad by design and covers product-condition refusals directly. Paired with the corresponding-responsibility doctrine for controlled substances, it means a New Jersey pharmacist is never obliged to dispense a product they reasonably believe is compromised.
Practice Scenarios
Scenario 1 — The sample on the shelf. During an inspection, a Board investigator finds three cartons marked "Professional Sample — Not for Sale" in the pharmacy's active stock. None has been dispensed. Analysis: A violation regardless. The RPIC must ensure that no drug marked "sample" or any like designation is dispensed or present in the active stock, and 13:39-7.18 addresses sample product specifically. Segregate and remove it through the disposal route in 13:39-7.17.
Scenario 2 — The refrigerator excursion. A pharmacy refrigerator logged 14°C overnight for nine hours. The insulin inside is well within its printed expiration date. Analysis: Undispensable. The product is improperly stored and presumptively deteriorated, and the printed date is irrelevant to that determination. Quarantine and follow the manufacturer's stability guidance; the temperature log is the evidence that will decide the outcome either way.
Scenario 3 — The Class I recall. A manufacturer announces a Class I recall of specific lots of a blood pressure medication for a probable carcinogenic impurity. The pharmacy has dispensed 40 prescriptions from affected lots in the past six months. Analysis: Quarantine remaining stock immediately, use dispensing records to identify affected patients, and follow the recall notice's patient-notification instructions. Class I is defined by a reasonable probability of serious adverse health consequences or death, which is what makes patient-level outreach appropriate rather than optional.
Scenario 4 — The bargain wholesaler. A pharmacy is offered a deeply discounted lot of a high-cost specialty drug by a distributor it cannot verify as an Authorized Trading Partner. Analysis: Do not purchase. Product acquired outside the authorized trading partner channel is suspect by origin under the DSCSA. If such product is already on hand, quarantine and investigate; if credible evidence establishes it is illegitimate, notify FDA on Form 3911 and immediate trading partners within 24 hours.
A Board inspector finds, in a pharmacy's active dispensing stock, one bottle three months past its expiration date and two cartons marked 'Professional Sample.' Nothing from either has been dispensed. What is the compliance posture?
A compounded cream is prepared in a work area later found to be visibly unsanitary, and a separately dispensed vial leaves the pharmacy without the federally required controlled substance transfer warning on its label. How are these two products characterized under the Food, Drug, and Cosmetic Act?
Which recall classification is defined by a reasonable probability that use of or exposure to the product will cause serious adverse health consequences or death?
A New Jersey pharmacist is offered a lot of specialty medication at a steep discount by a distributor the pharmacy cannot confirm as an Authorized Trading Partner, and a similar unverifiable lot is already sitting in the pharmacy's stock. Under the DSCSA, what is the correct handling of the product already on hand?